Boston Scientific BSX Cardiac Rhythm Management — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Boston Scientific in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Boston Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →
Ask your AI about Boston Scientific's cardiac rhythm management — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Boston Scientific's cardiac rhythm management — net sales?
- Boston Scientific (BSX) reported cardiac rhythm management — net sales of $578M in Q1 2026.
- How has Boston Scientific's cardiac rhythm management — net sales changed year-over-year?
- Boston Scientific's cardiac rhythm management — net sales decreased by 0.0% year-over-year, from $578M to $578M.
- What is the long-term trend for Boston Scientific's cardiac rhythm management — net sales?
- Over 4 years (2021 to 2025), Boston Scientific's cardiac rhythm management — net sales has grown at a 3.7% compound annual growth rate (CAGR), from $2.02B to $2.33B.
- What does cardiac rhythm management — net sales mean?
- Total revenue generated from the sale of heart rhythm management medical devices and related technologies.
- How do you interpret cardiac rhythm management — net sales?
- An increase suggests strong market adoption of the company's cardiac rhythm devices and successful clinical penetration, while a decrease may indicate increased competition, pricing pressure, or a shift in clinical treatment guidelines.
- How does cardiac rhythm management — net sales compare across companies?
- Comparable to revenue segments for cardiac rhythm management or electrophysiology divisions at major medical device competitors like Medtronic or Abbott Laboratories.